Literature DB >> 12665638

Physician treatment of osteoporosis in response to heel ultrasound bone mineral density reports.

Joan L Boyd1, John P Holcomb, R J Rothenberg.   

Abstract

Optimal information that should be included in ultrasound (US) heel bone mineral density (BMD) reports is not known. If additional information about further evaluation of patients with low heel BMD were included in reports, would responses for treatment improve? We screened people at health fairs using the Sahara heel US machine. For those with a T-score of </= 1.0, letters were sent to their primary care physician notifying them of the result. Physicians were randomly assigned to (1) a standard letter, which recommended central bone density screening (dual X-ray absorptiometry [DXA]) and treatment if the BMD was low; or (2) an extended letter, which also outlined treatment strategies based on recommended subsequent central DXA scan results for a T-score of < 1.50 and also if < 2.00. The extended letter only increased the frequency of DXA testing from 30.1 to 37.2% (not a significant increase). Of 88 people with heel BMD </= 1.00 and not previously on any treatment, 25 of 45 (56%) were treated (calcium, estrogens, bisphosphonates, or calcitonin or a combination) after physicians received a standard letter and 30 of 43 (70%) after an extended letter (one-sided p = 0.084). Of people with T </= 1.9, and initially taking nothing more than calcium, 5 of 36 (13.9%) received additional treatment after physicians received a standard letter vs 9 of 41 (22.0%) after an extended letter (one-sided p = 0.180). For those with T </= 1.0 because of the screen 25 of 197 (12.7%) received additional treatment. One hundred forty-six of 194 (75%) individuals and received treatment with calcium or other medications, and 74 of 173 (43%) of individuals before screening and 141 of 195 (72%) after physicians received letters took calcium. Physicians regarded calcium alone as adequate treatment in many cases. There was no marked increase in treatment when additional information was provided to physicians regarding evaluation and treatment for low US heel BMD results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12665638     DOI: 10.1385/jcd:5:4:375

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.963


  6 in total

1.  Dynamic acoustic radiation force retains bone structural and mechanical integrity in a functional disuse osteopenia model.

Authors:  Sardar M Z Uddin; Yi-Xian Qin
Journal:  Bone       Date:  2015-02-07       Impact factor: 4.398

2.  Complex interventions can increase osteoporosis investigations and treatment: a systematic review and meta-analysis.

Authors:  M Kastner; L Perrier; S E P Munce; C C Adhihetty; A Lau; J Hamid; V Treister; J Chan; Y Lai; S E Straus
Journal:  Osteoporos Int       Date:  2017-10-18       Impact factor: 4.507

3.  Reversal of the detrimental effects of simulated microgravity on human osteoblasts by modified low intensity pulsed ultrasound.

Authors:  Sardar M Z Uddin; Michael Hadjiargyrou; Jiqi Cheng; Shu Zhang; Minyi Hu; Yi-Xian Qin
Journal:  Ultrasound Med Biol       Date:  2013-02-27       Impact factor: 2.998

Review 4.  Interventions for improving the appropriate use of imaging in people with musculoskeletal conditions.

Authors:  Simon D French; Sally Green; Rachelle Buchbinder; Hayley Barnes
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 5.  Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials.

Authors:  Monika Kastner; Sharon E Straus
Journal:  J Gen Intern Med       Date:  2008-10-04       Impact factor: 5.128

6.  Health risks and changes in self-efficacy following community health screening of adults with serious mental illnesses.

Authors:  Judith A Cook; Lisa A Razzano; Margaret A Swarbrick; Jessica A Jonikas; Chantelle Yost; Larisa Burke; Pamela J Steigman; Alberto Santos
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.